Glucoryl-MP1 Tablet SR is a fixed-dose combination medication containing Glimepiride (1mg), Metformin (500mg), and Pioglitazone (15mg), formulated for sustained release to optimize glycemic control in patients with type 2 diabetes mellitus. Glimepiride, a sulfonylurea, stimulates pancreatic beta-cell insulin secretion, thereby reducing blood glucose levels. Metformin, a biguanide, primarily decreases hepatic glucose production and improves peripheral insulin sensitivity, contributing to enhanced glucose uptake by muscle tissues. Pioglitazone, a thiazolidinedione, acts as an insulin sensitizer by activating peroxisome proliferator-activated receptor gamma (PPAR-γ), which modulates the transcription of insulin-responsive genes involved in glucose and lipid metabolism. The combination of these agents targets multiple pathophysiological defects in type 2 diabetes, providing complementary mechanisms to achieve better glycemic control compared to monotherapy. Glucoryl-MP1 Tablet SR is indicated as an adjunct to diet and exercise to improve glycemic control in adults inadequately controlled on monotherapy or dual therapy. The sustained-release formulation allows for once-daily dosing, enhancing patient compliance. Caution is advised in patients with hepatic or renal impairment, and contraindications include severe renal dysfunction, diabetic ketoacidosis, and hypersensitivity to any component. Regular monitoring of blood glucose, liver function, and hematologic parameters is recommended during therapy.